<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-5-7</article-id><article-id pub-id-type="pmid">15040808</article-id><article-id pub-id-type="doi">10.1186/1471-2350-5-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Glutathione S-Transferase &#x003a9; 1 variation does not influence age at onset of Huntington's disease</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Arning</surname><given-names>Larissa</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>larissa.arning@rub.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Jagiello</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>peter.jagiello@rub.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Wieczorek</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stefan.wieczorek@rub.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Saft</surname><given-names>Carsten</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>carsten.saft@cityweb.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Andrich</surname><given-names>J&#x000fc;rgen</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>juergen.andrich@rub.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Epplen</surname><given-names>J&#x000f6;rg T</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>joerg.t.epplen@rub.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Human Genetics, Ruhr-University, 44780 Bochum, Germany</aff><aff id="I2"><label>2</label>Department of Neurology, St. Josef-Hospital, Ruhr-University, 44791 Bochum, Germany</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>24</day><month>3</month><year>2004</year></pub-date><volume>5</volume><fpage>7</fpage><lpage>7</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/5/7"/><history><date date-type="received"><day>5</day><month>1</month><year>2004</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Arning et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Arning et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><sec><title>Background</title><p>Huntington's disease (HD) is a fully penetrant, autosomal dominantly inherited disorder associated with abnormal expansions of a stretch of perfect CAG repeats in the 5' part of the <italic>IT15 </italic>gene. The number of repeat units is highly predictive for the age at onset (AO) of the disorder. But AO is only modestly correlated with repeat length when intermediate HD expansions are considered. Circumstantial evidence suggests that additional features of the HD course are based on genetic traits. Therefore, it may be possible to investigate the genetic background of HD, <italic>i.e</italic>. to map the loci underlying the development and progression of the disease. Recently an association of Glutathione S-Transferase &#x003a9; 1 <italic>(GSTO1) </italic>and possibly of <italic>GSTO2 </italic>with AO was demonstrated for, both, Alzheimer's (AD) and Parkinson's disease (PD).</p></sec><sec sec-type="methods"><title>Methods</title><p>We have genotyped the polymorphisms rs4925 <italic>GSTO1 </italic>and rs2297235 <italic>GSTO2 </italic>in 232 patients with HD and 228 controls.</p></sec><sec><title>Results</title><p>After genotyping <italic>GSTO1 </italic>and <italic>GSTO2 </italic>polymorphisms, firstly there was no statistically significant difference in AO for HD patients, as well as secondly for HD patients vs. controls concerning, both, genotype and allele frequencies, respectively.</p></sec><sec><title>Conclusion</title><p>The <italic>GSTO1 </italic>and <italic>GSTO2 </italic>genes flanked by the investigated polymorphisms are not comprised in a primary candidate region influencing AO in HD.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>HD is an autosomal dominantly transmitted, progressive, neurodegenerative disorder that is associated with an expanded block of CAG repeats in exon 1 of the <italic>IT15 </italic>gene (chromosome 4p) which encodes the protein huntingtin. The CAG repeat mutation is translated into an abnormally long polyglutamine tract, which is believed to acquire a deleterious gain of function in the mutant protein. However, though variation in repeat length may explain some of the variation in AO and, together with the observed progression of expansion over generations, it provides a molecular basis for the phenomenon of anticipation, other variables play a role, particularly in those cases where pathological CAG repeat numbers range in the high 30s or low 40s [<xref ref-type="bibr" rid="B1">1</xref>]. This insight has prompted the search for additional genes influencing AO in HD. Defining such independent predisposition factors is of paramount importance, since they may provide further clues pertaining to the pathology arising from the expanded repeats.</p><p>Recent association studies showed that single nucleotide polymorphisms (SNP) in the <italic>GSTO1 </italic>and <italic>GSTO2 </italic>gene region are associated with AO in AD and PD, rendering this region a likely candidate to affect AO in other neurodegenerative diseases, too [<xref ref-type="bibr" rid="B2">2</xref>]. The GSTs belong to a family of enzymes that utilize glutathione in reactions contributing to the transformation of a wide range of exogenous and endogenous compounds, including drugs, carcinogens, and the products of oxidative stress [OMIM 60548]. Therefore, the <italic>GSTO1 </italic>and <italic>GSTO2 </italic>genotypes were determined for HD patients that had previously been analysed with respect to CAG repeat length.</p></sec><sec sec-type="methods"><title>Methods</title><p>232 patients with clinical diagnosis of HD were recruited from the Huntington Center (HZ) NRW. Clinical assessment and determination of AO was performed exclusively by experienced neurologists/psychiatrists of the HZ NRW. The motor AO was ascertained by the clinical specialists for 143 patients. Controls (healthy blood donors from the German populations of Essen and Hamburg) were also genotyped for comparison. All patients and controls had given informed consent for genotyping.</p><p>CAG repeat sizes were determined after PCR amplification of genomic DNA from peripheral white blood cells. CAG repeats were amplified by established methods [<xref ref-type="bibr" rid="B3">3</xref>]. The polymorphism Ala140Asp (rs4925) of the <italic>GSTO1 </italic>gene was demonstrated after PCR amplification using the following primers: 5'-AAAGTTGTTTCTTAAACGTGCC-3' and 5'-AAGTGACTTGGAAAGTGGGAA-3'. PCR was carried out in a final volume of 20 &#x003bc;l with 50 ng of DNA, 200 &#x003bc;M dNTP and 0.25 U Taq Polymerase. Thermal cycling was performed with an initial activation step at 95&#x000b0;C for 15 min; 35 cycles of denaturation at 94&#x000b0;C for 1 min, annealing at 55&#x000b0;C for 1 min and extension at 72&#x000b0;C for 1 min; and a final extension at 72&#x000b0;C for 10 min. PCR products were digested with the restriction enzyme Cac8 I at 37&#x000b0;C overnight and visualised on 2% agarose gels stained with ethidium bromide. This digestion reveals a bi-allelic polymorphism with altogether 4 bands of different sizes: a 388 bp fragment (together with a 67 bp band) corresponding to the A allele (restriction site absent) as well as a set of 243, 145 and 67 bp fragmenst corresponding to the C allele (restriction sites present).</p><p>The transition polymorphism A to G (rs2297235) in the <italic>GSTO2 </italic>gene was demonstrated using the following primers: 5'-TTACTTACCAAAGAGTGGCCAG-3' and 5'-CCGCAGGCTCCAGAAAC-3' under the same conditions mentioned above. PCR products were digested with the restriction enzyme Tsp509 I at 65&#x000b0;C overnight. The digestion reveals a bi-allelic polymorphism with altogether 5 bands of different sizes: a 344 bp fragment specific for the G allele (one restriction site absent) <italic>vs</italic>. a set of 282, 62, 52 and 5 bp corresponding to the A allele (restriction sites present).</p><p>The variability in AO attributable to the CAG repeat number was calculated by linear regression. For the regression analysis, we used the AO as the dependent variable, and the size of the expanded CAG block, normal CAG repeat, their interaction, and the rs4925 <italic>GSTO1 </italic>as well as the rs2297235 <italic>GSTO2 </italic>genotypes as independent variables. SPSS, Ver.11.0 for Windows (SPSS Inc.), was used for all statistical analyses.</p></sec><sec><title>Results and discussion</title><p>In the cohort with defined AO, the mean AO (&#x000b1;SD) was 47.61 (&#x000b1;8.7) years (range 25&#x02013;73). The expanded CAG repeat ranged from 41&#x02013;45 (mean &#x000b1; SD: 42.94 &#x000b1; 1.2) and the unexpanded repeat size ranged from 13&#x02013;29 (mean &#x000b1; SD: 18.67 &#x000b1; 2.8; one individual had a smaller allele carrying 37 trinucleotides). As detailed in an earlier study concerning the clinically thoroughly characterised HD cohort [<xref ref-type="bibr" rid="B4">4</xref>], AO is negatively correlated with repeat lengths also in the lower range of CAG expansions. The CAG repeat length on normal chromosomes and the interaction failed to show any association with the age of onset of HD (Table <xref ref-type="table" rid="T1">1</xref>). The expanded CAG repeat explained 27.7% of the variance in AO. This relatively low value may be explained by the small range of CAG repeats (41&#x02013;45) investigated. Adding the unexpanded CAG repeat and the interaction term in the model did not affect the variance of the AO variance explained (from 27.7 to 27.8%). With respect to the small CAG repeat range the results are in agreement with a recently published study which showed a positive association with delayed AO of HD only for expansions &#x02265; 47 CAG [<xref ref-type="bibr" rid="B5">5</xref>]. In order to increase statistical power, further DNA samples of HD patients were included in these <italic>GSTO </italic>polymorphism studies. Both SNPs in the <italic>GST</italic>O region showed a virtually identical association pattern due to the LD between these two. Nevertheless, a rare haplotype (<italic>GSTO1 &#x02013; GSTO2</italic>, <italic>ac-aa</italic>) was more prevalent among HD patients compared to controls. This difference was statistically insignificant. Thus all in all, the distribution of the genotypes and allele frequencies between HD and control subjects was not statistically different (Table <xref ref-type="table" rid="T2">2</xref>). Observed frequencies were in Hardy-Weinberg equilibrium. Furthermore, the rs4925 <italic>GSTO1 </italic>and rs2297235 <italic>GSTO2 </italic>genotypes failed to show any association with the AO of HD (Table <xref ref-type="table" rid="T1">1</xref>, Fig. <xref ref-type="fig" rid="F1">1</xref> and Fig. 2).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Regression coefficients (SE) of the AO in dependence of the size of expanded CAG, normal CAG repeat, their interaction, and the rs4925 <italic>GSTO1 </italic>and rs2297235 <italic>GSTO2 </italic>genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Regression coefficients (SE)</bold></td><td align="center"><bold>P</bold></td></tr></thead><tbody><tr><td align="center">Expanded CAG size</td><td align="center">-3.842 (0.522)</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="center">Unexpanded CAG size</td><td align="center">-0.0228 (0.199)</td><td align="center">0.909</td></tr><tr><td align="center">Expanded* unexpanded CAG size</td><td align="center">-0.000527 (0.005)</td><td align="center">0.909</td></tr><tr><td align="center">rs4925 <italic>GSTO1</italic></td><td align="center">-0.841 (1.042)</td><td align="center">0.421</td></tr><tr><td align="center">rs2297235 <italic>GSTO2</italic></td><td align="center">-1.720 (1.042)</td><td align="center">0.095</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Allele and genotype frequencies of the <italic>GSTO1 </italic>and <italic>GSTO2 </italic>variations in HD patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Patients (n = 232)</bold></td><td align="center"><bold>Controls (n = 228)</bold></td></tr></thead><tbody><tr><td align="center">Alleles (%)</td><td align="center"><italic>GSTO1/GSTO2</italic></td><td align="center"><italic>GSTO1/GSTO2</italic></td></tr><tr><td align="center">A/G</td><td align="center">168 (36%)/151 (33%)</td><td align="center">142 (31%)/134 (29%)</td></tr><tr><td align="center">C/A</td><td align="center">296 (64%)/313 (67%)</td><td align="center">314 (69%)/322 (71%)</td></tr><tr><td align="center">Genotypes</td><td></td><td></td></tr><tr><td align="center">aa/gg</td><td align="center">28 (12%)/24 (10.3%)</td><td align="center">22 (10%)/20 (9%)</td></tr><tr><td align="center">ac/ga</td><td align="center">112 (48%)/103 (44.4%)</td><td align="center">98 (43%)/94 (41%)</td></tr><tr><td align="center">cc/aa</td><td align="center">92 (40%)/105 (45.3%)</td><td align="center">108 (47%)/114 (50%)</td></tr></tbody></table></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>a and b</bold>. Relationship between <italic>GSTO </italic>genotypes and AO for 143 HD patients. For each genotype, the median AO is represented as black bar, the quartile is shown as solid box and the range is indicated by the margins. Differences are statistically insignificant.</p></caption><graphic xlink:href="1471-2350-5-7-1"/></fig><p>The presence of insoluble protein aggregates within neurons is a common hallmark of AD, PD and HD [<xref ref-type="bibr" rid="B6">6</xref>]. These aggregates associated with the three neurodegenerative disorders may represent a common final pathway by compromising the axonal transport through trapping of molecules which are essential for cellular function such as chaperons and the proteasomes [<italic>op</italic>. <italic>cit</italic>.] The AD-causing mutations in the amyloid precursor protein (APP) render valuable clues as to the mechanisms of the disease and point to the relevance of amyloid &#x003b2;-protein (A&#x003b2;) toxicity in sporadic AD. In addition, the highly penetrant mutations of early-onset AD and PD implicate either A&#x003b2; or its precursor, APP, and &#x003b1;-synuclein as a cause of the toxicity and neuronal loss. The APOE*E4 as a risk factor for sporadic AD has contributed further to this understanding by adding cholesterol and lipid metabolisms to the model for A&#x003b2; toxicity [<xref ref-type="bibr" rid="B7">7</xref>]. As recently reported GSTO1 may be involved in the activation of interleukin 1 (IL-1&#x003b2;), and thus variation in GSTO1 could alter the efficacy of IL-1&#x003b2; post-translational processing, modulating any inflammatory response [<xref ref-type="bibr" rid="B8">8</xref>]. In particular, since IL-1&#x003b2; is induced by A&#x003b2; peptide, our results suggest different modifying mechanisms for AO in HD in comparison to AD and PD, the latter two entities being perhaps more closely related to each other in this aspect. This assumption is further substantiated by findings which could not confirm the AO-delaying effect of the &#x003b5;<italic>4 </italic>allele of the <italic>ApoE </italic>genotype in HD [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>In conclusion, the rs4925 <italic>GSTO1 </italic>and rs2297235 <italic>GSTO2 </italic>genotypes failed to show any association with the AO of HD. Furthermore, we found no evidence that the expanded and unexpanded CAG repeats interact to influence the AO of HD in the range of 41&#x02013;45 repeats.</p></sec><sec><title>Competing interests</title><p>None declared.</p></sec><sec><title>Authors' contributions</title><p>LA initiated the study, carried out the molecular genetic studies and drafted the manuscript. PJ and SW assisted in data assembly and analysis. JA and CS had ascertained the clinical status of the patients, and JTE participated in the study design, the coordination and finalized the analyses as well as the paper.</p><p>All authors read and approved the final version of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/5/7/prepub"/></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kehoe</surname><given-names>P</given-names></name><name><surname>Krawczak</surname><given-names>M</given-names></name><name><surname>Harper</surname><given-names>PS</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>AL</given-names></name></person-group><article-title>Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length</article-title><source>J Med Genet</source><year>1999</year><volume>36</volume><fpage>108</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">10051007</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Oliveira</surname><given-names>SA</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Stenger</surname><given-names>JE</given-names></name><name><surname>Scherzer</surname><given-names>CR</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Small</surname><given-names>GW</given-names></name><name><surname>Nance</surname><given-names>MA</given-names></name><name><surname>Watts</surname><given-names>RL</given-names></name><name><surname>Hubble</surname><given-names>JP</given-names></name><name><surname>Koller</surname><given-names>WC</given-names></name><name><surname>Pahwa</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>MB</given-names></name><name><surname>Hiner</surname><given-names>BC</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Mastaglia</surname><given-names>F</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name><name><surname>Saunders</surname><given-names>AM</given-names></name><name><surname>Schmechel</surname><given-names>DE</given-names></name><name><surname>Gullans</surname><given-names>SR</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Glutathione S-Transferase Omega 1 modifies age-at-onset of Alzheimer Disease and Parkinson Disease</article-title><source>Hum Mol Genet</source><year>2003</year><volume>24</volume><fpage>3259</fpage><lpage>3267</lpage><pub-id pub-id-type="pmid">14570706</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddg357</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>JP</given-names></name><name><surname>Barron</surname><given-names>LH</given-names></name><name><surname>Brock</surname><given-names>DJ</given-names></name></person-group><article-title>A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes</article-title><source>Mol Cell Probes</source><year>1993</year><volume>7</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">8366869</pub-id><pub-id pub-id-type="doi">10.1006/mcpr.1993.1034</pub-id></citation></ref><ref id="B4"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Brune</surname><given-names>N</given-names></name><name><surname>Andrich</surname><given-names>J</given-names></name><name><surname>Gencik</surname><given-names>M</given-names></name><name><surname>Saft</surname><given-names>C</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>T</given-names></name><name><surname>Valentin</surname><given-names>S</given-names></name><name><surname>Przuntek</surname><given-names>H</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name></person-group><article-title>Methyltetrahydrofolate Reductase polymorphism influences <italic>onset of Huntington's disease</italic></article-title><source>J Neural Transm</source><comment></comment></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Djousse</surname><given-names>L</given-names></name><name><surname>Knowlton</surname><given-names>B</given-names></name><name><surname>Hayden</surname><given-names>M</given-names></name><name><surname>Almqvist</surname><given-names>EW</given-names></name><name><surname>Brinkman</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>C</given-names></name><name><surname>Margolis</surname><given-names>R</given-names></name><name><surname>Rosenblatt</surname><given-names>A</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Dode</surname><given-names>C</given-names></name><name><surname>Morrison</surname><given-names>PJ</given-names></name><name><surname>Novelletto</surname><given-names>A</given-names></name><name><surname>Frontali</surname><given-names>M</given-names></name><name><surname>Trent</surname><given-names>RJ</given-names></name><name><surname>McCusker</surname><given-names>E</given-names></name><name><surname>Gomez-Tortosa</surname><given-names>E</given-names></name><name><surname>Mayo</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Zanko</surname><given-names>A</given-names></name><name><surname>Nance</surname><given-names>M</given-names></name><name><surname>Abramson</surname><given-names>R</given-names></name><name><surname>Suchowersky</surname><given-names>O</given-names></name><name><surname>Paulsen</surname><given-names>J</given-names></name><name><surname>Harrison</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Gusella</surname><given-names>JF</given-names></name><name><surname>MacDonald</surname><given-names>ME</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name></person-group><article-title>Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease</article-title><source>Am J Med Genet</source><year>2003</year><volume>3</volume><fpage>279</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.20190</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>JP</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Fischbeck</surname><given-names>KH</given-names></name></person-group><article-title>Toxic proteins in neurodegenerative diseases</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>1991</fpage><lpage>1995</lpage><pub-id pub-id-type="pmid">12065827</pub-id><pub-id pub-id-type="doi">10.1126/science.1067122</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LaDu</surname><given-names>MJ</given-names></name><name><surname>Shah</surname><given-names>JA</given-names></name><name><surname>Reardon</surname><given-names>CA</given-names></name><name><surname>Getz</surname><given-names>GS</given-names></name><name><surname>Bu</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>van Eldik</surname><given-names>LJ</given-names></name></person-group><article-title>Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures</article-title><source>J Biol Chem</source><year>2000</year><volume>43</volume><fpage>33974</fpage><lpage>33980</lpage><pub-id pub-id-type="pmid">10940295</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M000602200</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laliberte</surname><given-names>RE</given-names></name><name><surname>Perregaux</surname><given-names>DG</given-names></name><name><surname>Hoth</surname><given-names>LR</given-names></name><name><surname>Rosner</surname><given-names>PJ</given-names></name><name><surname>Jordan</surname><given-names>CK</given-names></name><name><surname>Peese</surname><given-names>KM</given-names></name><name><surname>Eggler</surname><given-names>JF</given-names></name><name><surname>Dombroski</surname><given-names>MA</given-names></name><name><surname>Geoghegan</surname><given-names>KF</given-names></name><name><surname>Gabel</surname><given-names>CA</given-names></name></person-group><article-title>Glutathione s-transferase omega 1&#x02013;1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>16567</fpage><lpage>16578</lpage><pub-id pub-id-type="pmid">12624100</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M211596200</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Leggo</surname><given-names>J</given-names></name><name><surname>Chiano</surname><given-names>M</given-names></name><name><surname>Dodge</surname><given-names>A</given-names></name><name><surname>Norbury</surname><given-names>G</given-names></name><name><surname>Rosser</surname><given-names>E</given-names></name><name><surname>Craufurd</surname><given-names>D</given-names></name></person-group><article-title>Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>8</volume><fpage>3872</fpage><lpage>3876</lpage><pub-id pub-id-type="pmid">9108071</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.8.3872</pub-id></citation></ref></ref-list></back></article> 